Advertisement

Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours

  • Daniel KaemmererEmail author
  • Luisa Peter
  • Amelie Lupp
  • Stefan Schulz
  • Jörg Sänger
  • Vikas Prasad
  • Harshad Kulkarni
  • Sven-Petter Haugvik
  • Merten Hommann
  • Richard Paul Baum
Original Article

Abstract

Purpose

Somatostatin receptors (SSTR) are known for an overexpression in gastroenteropancreatic neuroendocrine tumours (GEP-NET). The aim of the present study was to find out if the receptor density predicted by the semi-quantitative parameters generated from the static positron emission tomography (PET/CT) correlated with the in vitro immunohistochemistry using a novel rabbit monoclonal anti-SSTR2A antibody (clone UMB-1) for specific SSTR2A immunohistochemistry and polyclonal antibodies for SSTR1 and 3–5.

Methods

Overall 14 surgical specimens generated from 34 histologically documented GEP-NET patients were correlated with the preoperative 68Ga-DOTA-NOC PET/CT. Quantitative assessment of the receptor density was done using the immunoreactive score (IRS) of Remmele and Stegner; the additional 4-point IRS classification for immunohistochemistry and standardized uptake values (SUVmax and SUVmean) were used for PET/CT.

Results

The IRS for SSTR2A and SSTR5 correlated highly significant with the SUVmax on the PET/CT (p < 0.001; p < 0.05) and the IRS for SSTR2A with the SUVmean (p < 0.013). The level of SSTR2A score correlated significantly with chromogranin A staining and indirectly to the tumour grading.

Conclusion

The highly significant correlation between SSTR2A and SSTR5 and the SUVmax on the 68Ga-DOTA-NOC PET/CT scans is concordant with the affinity profile of 68Ga-DOTA-NOC to the SSTR subtypes and demonstrates the excellent qualification of somatostatin analogues in the diagnostics of NET. This study correlating somatostatin receptor imaging using 68Ga-DOTA-NOC PET/CT with immunohistochemically analysed SSTR also underlines the approval of therapy using somatostatin analogues, follow-up imaging as well as radionuclide therapy.

Keywords

Neuroendocrine tumour Somatostatin receptor imaging Somatostatin receptor immunohistochemistry Clone UMB-1 

Notes

Acknowledgement

Each author has contributed significantly to the submitted work. Daniel Kaemmerer had the conception, designed and performed the study and surgery, collected the tumours and drafted the manuscript. Luisa Peter performed the study, analysed, interpreted the data and wrote the manuscript. Sven-Petter Haugvik operated on the patients, critically contributed and revised the manuscript. Amelie Lupp developed the antibodies, contributed to the conception and to acquiring the data. Stefan Schulz developed the antibodies, critically revised and approved the final manuscript. Jörg Sänger analysed and interpreted the data and enhanced the intellectual content. Vikas Prasad contributed to the conception, performed the PET/CT imaging and analysed the data. Harshad Kulkarni revised and approved the final manuscript. Richard Paul Baum contributed to the conception, performed the PET/CT imaging and critically revised and approved the final manuscript. Merten Hommann performed the surgery, collected the tumours and critically revised and approved the final manuscript.

Conflicts of interest

None.

References

  1. 1.
    Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80 Suppl 1:51–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 2005;52:605–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 2008;93:4519–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRefGoogle Scholar
  5. 5.
    Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47.PubMedCrossRefGoogle Scholar
  8. 8.
    Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008;52:334–40.PubMedGoogle Scholar
  11. 11.
    McCarty Jr KS, Miller LS, Cox EB, Konrath J, McCarty Sr KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716–21.PubMedGoogle Scholar
  12. 12.
    Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010;42:220–5PubMedCrossRefGoogle Scholar
  13. 13.
    Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994;733:122–37.PubMedCrossRefGoogle Scholar
  14. 14.
    Reubi JC, Waser B, van Hagen M, Lamberts SW, Krenning EP, Gebbers JO, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992;50:895–900.PubMedCrossRefGoogle Scholar
  15. 15.
    Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Schulz S, Schmidt H, Händel M, Schreff M, Höllt V. Differential distribution of alternatively spliced somatostatin receptor 2 isoforms (sst2A and sst2B) in rat spinal cord. Neurosci Lett 1998;257:37–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Schulz S, Schreff M, Schmidt H, Händel M, Przewlocki R, Höllt V. Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. Eur J Neurosci 1998;10:3700–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998;4:2047–52.PubMedGoogle Scholar
  21. 21.
    Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 2006;59:274–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Reubi JC. Peptide receptor expression in GEP-NET. Virchows Arch 2007;451 Suppl 1:S47–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Reubi JC, Krenning E, Lamberts SW, Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990;37:1073–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Stivanello M, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001;12 Suppl 2:S73–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823–7.PubMedGoogle Scholar
  26. 26.
    Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455–9.PubMedGoogle Scholar
  27. 27.
    Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.PubMedCrossRefGoogle Scholar
  28. 28.
    Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36:48–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Daniel Kaemmerer
    • 1
    Email author
  • Luisa Peter
    • 2
  • Amelie Lupp
    • 2
  • Stefan Schulz
    • 2
  • Jörg Sänger
    • 3
  • Vikas Prasad
    • 4
  • Harshad Kulkarni
    • 4
  • Sven-Petter Haugvik
    • 1
  • Merten Hommann
    • 1
  • Richard Paul Baum
    • 4
  1. 1.Department of General and Visceral SurgeryZentralklinik Bad Berka GmbHBad BerkaGermany
  2. 2.Department of Pharmacology and ToxicologyUniversity of JenaJenaGermany
  3. 3.Laboratory of Pathology and CytologyBad BerkaGermany
  4. 4.Department of Nuclear Medicine and Center for PETZentralklinik Bad BerkaBad BerkaGermany

Personalised recommendations